Cargando…

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib

BACKGROUNDS: Tirabrutinib is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, approved by the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for relapsed and refractory PCNSL in March 2020. Skin-related disorder (SRD)s are the most prevalent adverse events in tirabrutinib, wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Nobuyoshi, Kobayashi, Keiichi, Saito, Kuniaki, Onoda, Ryo, Seiya, Yosuke, Suzuki, Saki, Yamagishi, Yuki, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Nagane, Motoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648233/ http://dx.doi.org/10.1093/noajnl/vdab159.091

Ejemplares similares

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021)

STMO-9 Maximal safe glioma resection using high resolution exoscope
por: Saito, Kuniaki, et al.
Publicado: (2021)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma
por: Yuki, Yamagishi, et al.
Publicado: (2021)

NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
por: Kobayashi, Keiichi, et al.
Publicado: (2021)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

ML-06 Diagnostic value of liquid biopsy for CNS lymphoma by detection of specific gene mutations in the cerebrospinal fluid
por: Yamagishi, Yuki, et al.
Publicado: (2020)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

GEN-13 PAIRED MUTATIONAL ANALYSIS IN SECONDARY NERVOUS SYSTEM LYMPHOMA AND PCNSL SYSTEMIC RELAPSE REVEALS DRIVER MUTATION CANDIDATES IN THE CENTRAL NERVOUS SYSTEM
por: Sasaki, Nobuyoshi, et al.
Publicado: (2022)

NQPC-21 QOL EVALUATION IN THE TREATMENT COURSE OF CNS LYMPHOMA
por: Yamagishi, Yuki, et al.
Publicado: (2022)

ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

STMO-09 Recovery from speech deficit after injury to frontal aslant tract in glioma surgery
por: Saito, Kuniaki, et al.
Publicado: (2020)

ML-02 MULTIAGENT IMMUNOCHEMOTHERAPY, R-MPV-A, FOR PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Nagane, Motoo, et al.
Publicado: (2019)

ML-10 Tirabrutinib, a second-generation BTK inhibitor in relapsed and refractory primary CNS lymphoma: A single institute study
por: Mishima, Kazuhiko, et al.
Publicado: (2021)

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status
por: Tabei, Yusuke, et al.
Publicado: (2020)

PATH-05. A CASE OF PILOCYTIC ASTROCYTOMA HARBORING THE FGFR1 GENE MUTATION WITH A PREDOMINANT OLIGODENDROGLIOMA-LIKE COMPONENT
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

ML-13 The primary treatment outcomes and future problems of PCNSL elderly patients in our institute
por: Kambe, Atsushi, et al.
Publicado: (2020)

ML-14 Re-challenge and maintenance therapy of methotrexate for elderly PCNSL patients with low scored KPS
por: Yamaguchi, Takashi, et al.
Publicado: (2020)

Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma
por: Yamagishi, Yuki, et al.
Publicado: (2021)

ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group
por: Asano, Kenichiro, et al.
Publicado: (2020)

ML-16 First clinical experience of administration of Tirabrutinib for the patients with newly diagnosed primary central nervous system lymphoma
por: Onodera, Sho, et al.
Publicado: (2021)

ML-07 High expression of PD-L1 on tumor-associated macrophage is a predictive factor for favorable prognosis in PCNSL
por: Furuse, Motomasa, et al.
Publicado: (2020)

BT-09 CLINICAL AND MOLECULAR GENETIC FEATURE OF CEREBELLAR GLIOBLASTOMA
por: Iijima, Shohei, et al.
Publicado: (2019)

STMO-14 SURGICAL MANAGEMENT OF DEEP-SEATED GLIOMA AROUND THALAMUS
por: Saito, Kuniaki, et al.
Publicado: (2019)

COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF
por: Shimada, Daisuke, et al.
Publicado: (2019)

NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
por: Yamagishi, Yuki, et al.
Publicado: (2019)

Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib
por: Arakawa, Yoshiki, et al.
Publicado: (2023)

COT-20 PERIOPERATIVE STATUS OF SERUM D-DIMER LEVEL AND VENOUS THROMBOSIS IN PATIENTS WITH MALIGNANT BRAIN TUMOR
por: Shimada, Daisuke, et al.
Publicado: (2019)

NQPC-07 IMMEDIATE POSTOPERATIVE REHABILITATION FOR PATIENTS WITH NEWLY-DIAGNOSED GLIOMA
por: Ikeda, Mitsuyo, et al.
Publicado: (2019)

STMO-18 SUBPIAL RESECTION OF GLIOMA USING CUSA CLARITY
por: Saito, Kuniaki, et al.
Publicado: (2019)

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
por: Narita, Yoshitaka, et al.
Publicado: (2020)

STMO-01 APPLICATION OF THE AMINOLEVULINIC ACID HYDROCHLORIDE FOR INTRAOPERATIVE DETECTION OF MALIGNANT BRAIN TUMORS
por: Kobayashi, Keiichi, et al.
Publicado: (2019)

ML-12 MECHANISMS OF CELL DEATH INHIBITION THROUGH CHANGE IN SUBCELLULAR LOCALIZATION OF PIM-1 BY PIM1 GENE MUTATION RECURRENTLY FOUND IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Sasaki, Nobuyoshi, et al.
Publicado: (2019)

ML-9 TREATMENT OUTCOMES OF TIRABRUTINIB FOR RELAPSED AND REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A SINGLE INSTITUTE
por: Ohka, Fumiharu, et al.
Publicado: (2022)

NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
por: Taku, Mikiko, et al.
Publicado: (2019)

COT-03 EVALUATING FUNCTIONING AND DISABILITY OF A PATIENT WITH BRAIN TUMOR BY WHODAS
por: Ishita, Kohei, et al.
Publicado: (2019)

SS-1 Therapeutic challenges for glioblastoma: Temozolomide and its issues?
por: Nagane, Motoo
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0ip0p37ub1i593kdaq5chk6u3m